Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
NCT05131022 · View on ClinicalTrials.gov ↗
Study Summary
This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients with advanced B-cell malignancies.
Conditions Studied
Interventions
- DRUG NX-5948
Study Locations (20)
California
- City of Hope — Duarte
- University of California, San Francisco — San Francisco
Florida
- University of Miami — Miami
- Florida Cancer Specialists — Sarasota
New York
- Cayuga Medical Center — Ithaca
- Memorial Sloan Kettering Cancer Center — New York
Ohio
- University of Cincinnati Medical Center — Cincinnati
- Cleveland Clinic — Cleveland
Other
- CHU Angers — Angers
- Hôpital Avicenne — Bobigny
Colorado
- Colorado Blood Cancer Institute — Denver
Connecticut
- Yale Cancer Center — New Haven
Georgia
- Winship Cancer Institute of Emory University — Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 572 participants |
| Start Date | 2022-04-13 |
| Est. Completion | 2028-01 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05131022
The ClinicalTrials.gov registry entry for NCT05131022 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 572 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nurix Therapeutics, which has 36 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 9 conditions, with Chronic Lymphocytic Leukemia (CLL) appearing as the primary indexed condition, and to 1 intervention — of which NX-5948 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05131022 reports 20 study locations spanning 15 distinct geographic areas — top geographies include California, Florida, New York. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05131022 about?
NCT05131022 is a clinical study titled "A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies". This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients with advanced B-cell malignancies.
What is the current status of trial NCT05131022?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 572 participants. The study started on 2022-04-13. Estimated completion is 2028-01.
What conditions does trial NCT05131022 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma (MCL), Follicular Lymphoma (FL), Primary Central Nervous System Lymphoma (PCNSL). These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05131022?
The interventions under investigation include: NX-5948 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05131022?
This trial is sponsored by Nurix Therapeutics, which has 36 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05131022 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.